SCHEMBL22178703

SCHEMBL22178703

CC(C)(C)OCC(=O)NCC(=O)NCC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.39
ALDH1A1 P00352 5/20 0.34
LMNA P02545 2/20 0.34
MAPT P10636 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
RECQL P46063 2/20 0.34
PTGS2 P35354 1/20 0.34
FAAH O00519 5/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
POLB P06746 2/20 0.33
APEX1 P27695 2/20 0.33
KDM4E B2RXH2 1/20 0.33
USP2 O75604 1/20 0.33
CYP3A4 P08684 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33
GPR18 Q14330 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27641005 0.78 MAOA (0.40) ALDH1A1MAPTRECQLHPGDHSD17B10
SCHEMBL10026738 0.78 RECQL (0.35) ALDH1A1MAPTRECQLHPGDHSD17B10
SCHEMBL19901566 0.77 EGLN1 (0.39) EGLN1ALDH1A1LMNAMAPTTDP1
SCHEMBL1000860 0.77 MEN1 (0.46) EGLN1ALDH1A1LMNATDP1MEN1
SCHEMBL8500219 0.77 MEN1 (0.46) EGLN1ALDH1A1LMNATDP1MEN1
SCHEMBL999017 0.77 MEN1 (0.46) EGLN1ALDH1A1LMNATDP1MEN1
SCHEMBL1486144 0.77 MEN1 (0.46) EGLN1ALDH1A1LMNATDP1MEN1
SCHEMBL25540182 0.77 EPHX2 (0.40) RECQLFAAHMEN1KMT2AKDM4E
SCHEMBL24263063 0.76 RECQL (0.33) RECQLAAK1
SCHEMBL22971263 0.76 GAA (0.58) ALDH1A1MAPTRECQLMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040959-B2 Diprovocims: a new and potent class of TLR agonists THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-06-22 US disclosed
US-20200207742-A1 DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS THE SCRIPPS RESEARCH INSTITUTE 2020-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207742-A1 DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS TLR1, TLR4, TLR2 EGLN1 2750/4885ALDH1A1 3784/4885LMNA 3718/4885
US-11040959-B2 Diprovocims: a new and potent class of TLR agonists TLR1, TLR4, TLR2 EGLN1 2801/4885ALDH1A1 3696/4885LMNA 3618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.